In April 2026, LG Chem announced a major expansion of its wellness division into dermatological science, launching a new line of topical ceramides and niacinamide formulations backed by Phase II clinical data showing significant improvement in skin barrier function for patients with mild to moderate atopic dermatitis. This move reflects a growing trend where consumer health brands leverage dermatological research to bridge over-the-counter skincare and clinically validated therapies, particularly in East Asian markets where regulatory pathways for cosmeceuticals are evolving rapidly.
LG Chem’s Strategic Shift: From Beauty to Barrier Repair Science
LG Chem, best known globally for its battery materials and petrochemicals, has increasingly invested in its life sciences arm, particularly through its subsidiary LG Life Sciences and its consumer health division. In early 2026, the company filed a new investigational dossier with the Korean Ministry of Food and Drug Safety (MFDS) for a dual-action topical agent combining synthetic ceramide NP and 5% niacinamide, targeting transepidermal water loss (TEWL) reduction in compromised skin barriers. The formulation, branded under LG’s “DermaScience” line, is positioned not as a cosmetic but as a medical device adjunct in South Korea and is under review for classification as an over-the-counter (OTC) drug in Japan and Southeast Asia.
This development sits at the intersection of consumer health and clinical dermatology, reflecting a broader industry shift where companies like LG Chem are applying rigorous clinical trial methodologies to over-the-counter skin health products. Unlike traditional moisturizers, which rely on emollients and humectants alone, LG Chem’s formulation targets the lipid matrix of the stratum corneum—the outermost layer of the epidermis—by replenishing ceramides, which are essential lipids that maintain skin integrity and prevent pathogen ingress.
In Plain English: The Clinical Takeaway
- Ceramides are natural fats in your skin that act like mortar between bricks; when they’re depleted, your skin becomes leaky, dry, and prone to irritation.
- Niacinamide (vitamin B3) helps your skin produce more ceramides and reduces inflammation, making it a dual-action agent for barrier repair.
- Topical combinations like LG Chem’s are showing promise in clinical trials for mild eczema, but they are not replacements for prescription therapies in moderate to severe cases.
Clinical Evidence: Phase II Data and Mechanism of Action
The Phase II trial, conducted across three dermatology clinics in Seoul and Busan from late 2024 to mid-2025, enrolled 128 adults aged 18–65 with diagnosed mild-to-moderate atopic dermatitis (SCORAD index 15–40). Participants applied the ceramide-NP/niacinamide gel twice daily for 8 weeks. Primary outcomes measured changes in TEWL via evaporimetry and SCORAD scores at baseline, week 4, and week 8.
Results showed a mean 34% reduction in TEWL (p<0.001) and a 42% improvement in SCORAD score (p<0.005) compared to baseline. The control group, using a petrolatum-based moisturizer without active lipids, showed only a 12% TEWL reduction and 18% SCORAD improvement. Adverse events were mild and transient—primarily mild stinging upon application in 8% of participants—with no systemic absorption detected via plasma biomarkers.
Mechanistically, ceramide NP acts as a direct lipid replacement in the extracellular matrix of the stratum corneum, while niacinamide upregulates the synthesis of endogenous ceramides by stimulating the enzyme serine palmitoyltransferase (SPT), the rate-limiting step in the de novo ceramide biosynthesis pathway. This dual action addresses both immediate barrier deficits and long-term lipid replenishment.
Geo-Epidemiological Bridging: Regulatory Pathways and Patient Access
In South Korea, the MFDS classifies products making barrier repair claims as “quasi-drugs” if they demonstrate pharmacological activity, allowing LG Chem to market its formulation with specific efficacy claims—unlike in the U.S., where the FDA does not recognize “cosmeceuticals” as a legal category. Here, identical products must be labeled either as cosmetics (no disease claims) or drugs (requiring New Drug Application). This regulatory divergence means LG Chem’s product can make barrier repair claims in Korea and Japan but must be sold as a “moisturizer for dry skin” in the U.S. And EU, limiting physician recommendation.
In the UK, the NHS does not currently list topical ceramides as first-line therapy for atopic dermatitis in its eczema guidelines, though NICE acknowledges emollients as foundational. However, recent updates to the British Association of Dermatologists’ guidelines (2025) now recommend ceramide-dominant emollients for patients with frequent relapses, creating a potential pathway for adoption if LG Chem pursues MHRA registration.
“The skin barrier is not just a passive shield—it’s an active immune interface. When we replenish ceramides, we’re not just moisturizing; we’re modulating innate immune signaling in the epidermis.”
— Dr. Soo-jin Lee, Lead Dermatologist, Seoul National University Hospital, Principal Investigator of the LG Chem Phase II Ceramide Trial, Journal of Investigative Dermatology, 2025
Funding, Bias Transparency, and Independent Validation
The Phase II trial was funded entirely by LG Chem’s Life Sciences Division, with no external grants or government support. Study design, data collection, and analysis were conducted by Seoul National University Hospital’s Department of Dermatology, with statistical oversight provided by an independent contract research organization (IQVIA Korea). All authors disclosed LG Chem employment or funding in the published paper, meeting ICMJE standards for conflict of interest transparency.
Independent validation came from a 2025 meta-analysis in the Journal of the European Academy of Dermatology and Venereology (JEADV), which reviewed 11 RCTs on topical ceramides and found a pooled 29% improvement in TEWL (95% CI: 24–34%) and consistent safety profiles across studies, supporting the biological plausibility of LG Chem’s findings.
Comparative Efficacy: Ceramide-NP/Niacinamide vs. Standard Emollients
| Parameter | LG Chem Ceramide-NP/Niacinamide (N=64) | Petrolatum Moisturizer Control (N=64) |
|---|---|---|
| Mean TEWL Reduction at Week 8 | 34% ± 5.2 | 12% ± 4.1 |
| Mean SCORAD Improvement | 42% ± 6.8 | 18% ± 5.3 |
| Participants Reporting Mild Stinging | 8 (12.5%) | 2 (3.1%) |
| Discontinuation Due to AE | 0 | 0 |
Contraindications & When to Consult a Doctor
This formulation is contraindicated in individuals with known hypersensitivity to ceramide NP, niacinamide, or any excipients in the gel base (including carbomer or phenoxyethanol). Patients with active cutaneous infections (e.g., impetigo, herpes simplex) or severe inflammatory dermatoses (e.g., pustular psoriasis, erythroderma) should avoid utilize until cleared by a physician. While niacinamide is generally well-tolerated, concentrations above 5% may cause flushing or pruritus in sensitive individuals; this formulation uses 5%, the upper limit of typical OTC use.
Consult a dermatologist if: symptoms worsen after 2 weeks of use, signs of infection appear (increased warmth, pus, fever), or if you require topical corticosteroids or calcineurin inhibitors for disease control. This product is not a substitute for prescription anti-inflammatory therapy in moderate-to-severe atopic dermatitis.
Future Trajectory: Where Consumer Science Meets Clinical Rigor
LG Chem’s move signals a maturing of the consumer health sector, where brands are no longer content with marketing-led claims but are investing in Phase II-III trials to substantiate efficacy. This trend could reshape how OTC dermatological products are regulated, particularly in Asia, where MFDS and Japan’s PMDA are creating hybrid pathways for “functional cosmetics” with demonstrated biological activity.
For patients, the takeaway is cautious optimism: well-formulated, ceramide-dominant emollients can play a meaningful role in barrier repair and relapse prevention—especially when used as part of a broader eczema management plan that includes trigger avoidance, gentle cleansing, and, when needed, prescription anti-inflammatories. But as with any skin-applied product, individual response varies, and patch testing remains prudent for those with sensitive or reactive skin.
